TORRANCE, Calif., Jan. 28, 2019 /PRNewswire/ — Emmaus Life Sciences, Inc. (Emmaus), a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari™ (L-glutamine oral powder) [1] . The program is limited to financially eligible patients covered by commercial insurance.

A significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.

Mark Diamond, Emmaus’ Vice President of Commercialization, commented: “We are committed to removing barriers between patients and Endari – giving a greater number of patients access to our effective treatment for sickle cell disease.”

Click here to read the full press release.

Sickle Cell Disease Association of America, Inc. (SCDAA) in no way endorses any medications, treatments, clinical trials, or studies reported through Get Connected. Information is provided to keep the readers informed. Because the manifestations and severity of sickle cell vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.